On Tuesday, BMO Capital Markets adjusted its outlook on shares of AbCellera Biologics (NASDAQ:ABCL), reducing the price target to $5.00 from the previous $12.00. Despite this change, the firm maintained its Outperform rating on the stock. The adjustment follows the company's recent earnings report and business updates.
In a statement, BMO Capital highlighted AbCellera's strategic pivot towards internal development and ownership of its assets. This shift was underscored during the company's latest call with investors, where the focus was drawn to the development of ABCL635 and ABCL575.
These assets are anticipated to be key interest points for investors as they are expected to potentially enter clinical trials in 2025, following applications in the second quarter of that year.
The reduction in research revenues year-over-year was noted as a reflection of AbCellera's strategic transition to internal development. While this may present a near-term headwind, it is seen as a deliberate move towards a more lucrative business model. The company aims to leverage its proprietary antibody platform to develop in-house assets, which could offer higher rewards.
The new price target follows the third-quarter 2024 results, which have prompted a reassessment of the company's near-term financial outlook. BMO Capital's revised target reflects the current state of AbCellera's financials and its strategic direction as the company continues to execute its plan into 2025.
In other recent news, AbCellera reported steady Q3 2024 revenue of $7 million amidst a growth in R&D expenses, which led to a net loss of $51 million for the quarter. This loss includes a $32 million non-cash impairment charge due to the reprioritization of internal programs.
Despite this, AbCellera maintains a robust liquidity position, with approximately $670 million in cash and equivalents and $210 million in government funding, projecting sufficient funds for the next three years. The company has also announced its upcoming Clinical Trial Application (CTA) filings for its first two internal pipeline programs, ABCL635 and ABCL575, expected in Q2 2025.
Furthermore, the company has completed its headquarters move and is progressing on its GMP manufacturing facility, expected to be operational in 2025. In partnership news, AbCellera has expanded its collaboration with Eli Lilly (NYSE:LLY), focusing on co-development. These are among the recent developments for AbCellera as it transitions to a clinical-stage biotech company.
InvestingPro Insights
Recent InvestingPro data provides additional context to AbCellera Biologics' (NASDAQ:ABCL) current financial situation and market performance. The company's market capitalization stands at $851.58 million, with a price-to-book ratio of 0.79 as of the last twelve months ending Q3 2024. This valuation metric suggests the stock might be undervalued relative to its book value.
InvestingPro Tips highlight that AbCellera holds more cash than debt on its balance sheet, which could provide financial flexibility as the company transitions towards internal development. However, the company is also quickly burning through cash, which aligns with BMO Capital's observation of near-term headwinds due to the strategic shift.
The revenue for the last twelve months ending Q3 2024 was $32.96 million, with a significant revenue decline of 34.59% over the same period. This decline correlates with the reduction in research revenues mentioned in the article, reflecting the company's pivot to internal asset development.
InvestingPro Tips also indicate that analysts do not anticipate the company to be profitable this year, which is consistent with the negative gross profit of $142.7 million and operating income of -$308.06 million for the last twelve months. These figures underscore the financial challenges AbCellera faces during its strategic transition.
Despite these challenges, the stock has shown a strong return over the last month, with a 15.6% price total return. This recent performance might reflect investor optimism about the company's long-term strategy, including the development of ABCL635 and ABCL575 mentioned in the article.
For investors seeking a more comprehensive analysis, InvestingPro offers additional tips and insights beyond those mentioned here. There are 8 more InvestingPro Tips available for AbCellera Biologics, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.